YiChang HEC ChangJiang Pharmaceutical 관리
관리 기준 확인 3/4
YiChang HEC ChangJiang Pharmaceutical CEO는 Juncai Jiang, May2015 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 CN¥ 2.57M, 18.7% 로 구성됩니다. 18.7% 급여 및 81.3% 보너스(회사 주식 및 옵션 포함). 는 HK$ 623.81K 가치에 해당하는 회사 주식의 0.008% 직접 소유합니다. 623.81K. 경영진과 이사회의 평균 재임 기간은 각각 7.3 년과 7.3 년입니다.
주요 정보
Juncai Jiang
최고 경영자
CN¥2.6m
총 보상
| CEO 급여 비율 | 18.7% |
| CEO 임기 | 9.5yrs |
| CEO 소유권 | 0.008% |
| 경영진 평균 재임 기간 | 7.3yrs |
| 이사회 평균 재임 기간 | 7.3yrs |
최근 관리 업데이트
Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07
Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥3m | CN¥482k | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥608m |
| Dec 31 2022 | CN¥1m | CN¥600k | CN¥77m |
| Sep 30 2022 | n/a | n/a | -CN¥18m |
| Jun 30 2022 | n/a | n/a | -CN¥113m |
| Mar 31 2022 | n/a | n/a | -CN¥351m |
| Dec 31 2021 | CN¥1m | CN¥490k | -CN¥588m |
| Sep 30 2021 | n/a | n/a | -CN¥436m |
| Jun 30 2021 | n/a | n/a | -CN¥285m |
| Mar 31 2021 | n/a | n/a | CN¥277m |
| Dec 31 2020 | CN¥756k | CN¥229k | CN¥839m |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥2b |
| Dec 31 2019 | CN¥393k | CN¥222k | CN¥2b |
| Sep 30 2019 | n/a | n/a | CN¥2b |
| Jun 30 2019 | n/a | n/a | CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥1b |
| Dec 31 2018 | CN¥365k | CN¥209k | CN¥943m |
| Sep 30 2018 | n/a | n/a | CN¥961m |
| Jun 30 2018 | n/a | n/a | CN¥980m |
| Mar 31 2018 | n/a | n/a | CN¥813m |
| Dec 31 2017 | CN¥324k | CN¥194k | CN¥647m |
보상 대 시장: Juncai 의 총 보상 ($USD 354.98K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 481.54K ).
보상과 수익: Juncai 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Juncai Jiang (42 yo)
9.5yrs
테뉴어
CN¥2,572,000
보상
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| GM & Executive Director | 9.5yrs | CN¥2.57m | 0.0076% HK$ 623.8k | |
| Head of the Sales Department | 10.5yrs | CN¥645.00k | 데이터 없음 | |
| Deputy GM & Executive Director | 9.5yrs | CN¥2.71m | 0.0076% HK$ 627.9k | |
| Deputy GM & Executive Director | 9.5yrs | CN¥1.32m | 0.0076% HK$ 623.8k | |
| Executive Director | 1.2yrs | CN¥1.59m | 데이터 없음 | |
| CFO & Head of Finance Department | 5.8yrs | CN¥480.38k | 데이터 없음 | |
| Chief of Quality Division & Employee Representative Supervisor | 7.3yrs | 데이터 없음 | 0.0036% HK$ 299.2k | |
| Joint Company Secretary | 6.1yrs | CN¥370.31k | 데이터 없음 | |
| Joint Company Secretary | 2.8yrs | 데이터 없음 | 데이터 없음 |
7.3yrs
평균 재임 기간
43yo
평균 연령
경험이 풍부한 관리: 1558 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| GM & Executive Director | 9.5yrs | CN¥2.57m | 0.0076% HK$ 623.8k | |
| Deputy GM & Executive Director | 18.8yrs | CN¥2.71m | 0.0076% HK$ 627.9k | |
| Deputy GM & Executive Director | 6.4yrs | CN¥1.32m | 0.0076% HK$ 623.8k | |
| Executive Director | 1.2yrs | CN¥1.59m | 데이터 없음 | |
| Chief of Quality Division & Employee Representative Supervisor | 7.3yrs | 데이터 없음 | 0.0036% HK$ 299.2k | |
| Non-Executive Chairman | 9.5yrs | CN¥32.19m | 0.015% HK$ 1.2m | |
| Independent Non-Executive Director | 9.5yrs | CN¥100.00k | 데이터 없음 | |
| Supervisor | 7.4yrs | 데이터 없음 | 0.0076% HK$ 623.8k | |
| Chairman of the Board of Supervisors | 5.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non Executive Director | 4.4yrs | CN¥100.00k | 데이터 없음 | |
| Independent Non-Executive Director | 4.2yrs | CN¥340.00k | 0.00045% HK$ 37.0k |
7.3yrs
평균 재임 기간
46yo
평균 연령
경험이 풍부한 이사회: 1558 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.